Company Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines.
Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2.
The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders.
In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment.
Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
| Country | United Kingdom |
| Founded | 2020 |
| IPO Date | May 28, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 114 |
| CEO | Mario Accardi |
Contact Details
Address: 1 Ashley Road, 3rd Floor Altrincham, WA14 2DT United Kingdom | |
| Website | centessa.com |
Stock Details
| Ticker Symbol | CNTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 1847903 |
| CUSIP Number | 152309100 |
| ISIN Number | US1523091007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mario Alberto Accardi Ph.D. | Chief Executive Officer and Director |
| Iqbal J. Hussain L.L.B. | Chief Legal Officer, Chief Compliance Officer and Company Secretary |
| Karen M. Anderson | Chief People Officer |
| Dr. Gregory M. Weinhoff M.B.A., M.D. | Chief Business Officer |
| Charlene Stoudt | Senior Vice President of Clinical Development Operations |
| Dr. Stephen J. Kanes M.D., Ph.D. | Head of Research & Development and Chief Medical Officer |
| Dr. Kimberly A. McCormick Pharm.D. | Senior Vice President of Regulatory Affairs and Medical Writing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 31, 2026 | 10-K | Annual Report |
| Mar 31, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 31, 2026 | DFAN14A | Filing |
| Mar 26, 2026 | 144 | Filing |